Literature DB >> 26969590

The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.

Cameron P Capper1, James M Rae1, Richard J Auchus2.   

Abstract

Breast and prostate cancers are malignancies in which steroid hormones drive cellular proliferation. Over the past century, this understanding has led to successful treatment strategies aimed to inhibit hormone-mediated tumor growth. Nonetheless, disease relapse and progression still pose significant clinical problems, with recurrent and metastatic tumors often exhibiting resistance to current drug therapies. The central role of androgens and estrogens in prostate and breast cancer etiology explains not only why endocrine therapies are often initially successful but also why many tumors ultimately become resistant. It is hypothesized that reducing the concentration of active hormones in the systemic circulation may be insufficient to block cancer progression, as this action selects for tumor cells that can generate active steroids from circulating precursors. This review aims to highlight the currently known differences of steroid biosynthesis in normal physiology versus hormone-dependent cancers, modern approaches to the assessment and targeting of these pathways, and priorities for future research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26969590      PMCID: PMC4860032          DOI: 10.1007/s12672-016-0259-0

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  126 in total

Review 1.  Principles for modulation of the nuclear receptor superfamily.

Authors:  Hinrich Gronemeyer; Jan-Ake Gustafsson; Vincent Laudet
Journal:  Nat Rev Drug Discov       Date:  2004-11       Impact factor: 84.694

2.  EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE.

Authors:  C Huggins
Journal:  Ann Surg       Date:  1942-06       Impact factor: 12.969

3.  Type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis.

Authors:  Yasuhiro Nakamura; Peter J Hornsby; Peter Casson; Ryo Morimoto; Fumitoshi Satoh; Yewei Xing; Michael R Kennedy; Hironobu Sasano; William E Rainey
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

4.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

5.  Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.

Authors:  Mark A Titus; Michael J Schell; Fred B Lih; Kenneth B Tomer; James L Mohler
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

6.  A canonical structure for the ligand-binding domain of nuclear receptors.

Authors:  J M Wurtz; W Bourguet; J P Renaud; V Vivat; P Chambon; D Moras; H Gronemeyer
Journal:  Nat Struct Biol       Date:  1996-01

7.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

Authors:  C Huggins; C V Hodges
Journal:  CA Cancer J Clin       Date:  1972 Jul-Aug       Impact factor: 508.702

Review 8.  History of aromatase: saga of an important biological mediator and therapeutic target.

Authors:  R J Santen; H Brodie; E R Simpson; P K Siiteri; A Brodie
Journal:  Endocr Rev       Date:  2009-04-23       Impact factor: 19.871

9.  Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Authors:  Juliet Richards; Ai Chiin Lim; Colin W Hay; Angela E Taylor; Anna Wingate; Karolina Nowakowska; Carmel Pezaro; Suzanne Carreira; Jane Goodall; Wiebke Arlt; Iain J McEwan; Johann S de Bono; Gerhardt Attard
Journal:  Cancer Res       Date:  2012-03-12       Impact factor: 12.701

10.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Authors:  Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

View more
  22 in total

1.  New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis.

Authors:  Ana F Castillo; Ulises D Orlando; Paula M Maloberti; Jesica G Prada; Melina A Dattilo; Angela R Solano; María M Bigi; Mayra A Ríos Medrano; María T Torres; Sebastián Indo; Graciela Caroca; Hector R Contreras; Belkis E Marelli; Facundo J Salinas; Natalia R Salvetti; Hugo H Ortega; Pablo Lorenzano Menna; Sergio Szajnman; Daniel E Gomez; Juan B Rodríguez; Ernesto J Podesta
Journal:  Cell Mol Life Sci       Date:  2020-10-17       Impact factor: 9.261

2.  Higher Dihydrotestosterone Is Associated with the Incidence of Lung Cancer in Older Men.

Authors:  Yi X Chan; Helman Alfonso; S A Paul Chubb; David J Handelsman; P Gerry Fegan; Graeme J Hankey; Jonathan Golledge; Leon Flicker; Bu B Yeap
Journal:  Horm Cancer       Date:  2017-02-23       Impact factor: 3.869

3.  Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition.

Authors:  Pulak R Manna; Ahsen U Ahmed; David Vartak; Deborah Molehin; Kevin Pruitt
Journal:  Biochem Biophys Res Commun       Date:  2018-12-27       Impact factor: 3.575

Review 4.  Hormonal Therapy for Prostate Cancer.

Authors:  Kunal Desai; Jeffrey M McManus; Nima Sharifi
Journal:  Endocr Rev       Date:  2021-05-25       Impact factor: 19.871

5.  Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.

Authors:  Jing Tian; Yong Wang; Xing Zhang; Qianyao Ren; Rong Li; Yue Huang; Huiling Lu; Jian Chen
Journal:  J Exp Clin Cancer Res       Date:  2017-11-02

6.  Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.

Authors:  Rohina Rubicz; Shanshan Zhao; Jonathan L Wright; Ilsa Coleman; Catherine Grasso; Milan S Geybels; Amy Leonardson; Suzanne Kolb; Craig April; Marina Bibikova; Dean Troyer; Raymond Lance; Daniel W Lin; Elaine A Ostrander; Peter S Nelson; Jian-Bing Fan; Ziding Feng; Janet L Stanford
Journal:  Mol Oncol       Date:  2016-10-19       Impact factor: 6.603

Review 7.  Metal complexes in cancer therapy - an update from drug design perspective.

Authors:  Umar Ndagi; Ndumiso Mhlongo; Mahmoud E Soliman
Journal:  Drug Des Devel Ther       Date:  2017-03-03       Impact factor: 4.162

Review 8.  Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics.

Authors:  Marcela Valko-Rokytovská; Peter Očenáš; Aneta Salayová; Zuzana Kostecká
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

Review 9.  The Metabolic Phenotype of Prostate Cancer.

Authors:  Eric Eidelman; Jeffrey Twum-Ampofo; Jamal Ansari; Mohummad Minhaj Siddiqui
Journal:  Front Oncol       Date:  2017-06-19       Impact factor: 6.244

10.  Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression.

Authors:  Marc Clos-Garcia; Ana Loizaga-Iriarte; Patricia Zuñiga-Garcia; Pilar Sánchez-Mosquera; Ana Rosa Cortazar; Esperanza González; Verónica Torrano; Cristina Alonso; Miriam Pérez-Cormenzana; Aitziber Ugalde-Olano; Isabel Lacasa-Viscasillas; Azucena Castro; Felix Royo; Miguel Unda; Arkaitz Carracedo; Juan M Falcón-Pérez
Journal:  J Extracell Vesicles       Date:  2018-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.